Ani Pharmaceuticals Inc. (ANIP)
ANI Pharmaceuticals reports Phase 4 data for uveitis eye implant
ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported positive topline data from a Phase 4 trial of its fluocinolone acetonide intravitreal implant in chronic non-infectious uveitis, drawing on results from its open-label SYNCHRONICITY study, the company said. ANI Pharmaceuticals said the SYNCHRONICITY trial was a Phase 4, open-label, single-arm study of the fluocinolone acetonide intravitreal implant in patients with chronic non-infectious uveitis affecting the posterior segment of the eye, a condition the company abbreviated as chronic NIU-PS.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple
ANI Pharmaceuticals is rated a speculative buy, with the investment thesis centered on Cortrophin Gel's rare disease revenue growth and transformation. Management guides to $540M-$575M Cortrophin revenue in 2026, making rare disease close to 60% of total revenue and supporting a re-rating. A $108 fair value is based on 9x 2026 adjusted EBITDA, offering ~30% upside if Cortrophin growth and gout expansion materialize as guided.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
ANIP Pharmaceuticals' Cortrophin Gel Drives 2026 Growth
ANI Pharmaceuticals ANIP is reshaping its growth profile. In 2025, revenue surged on the back of a rare disease franchise that is becoming the company's defining investment narrative.
Why ANI Pharmaceuticals (ANIP) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.
ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
